Another Eylea threat: Roche expands label for blockbuster eye drug Vabysmo

With hopes of dethroning Regeneron’s blockbuster eye drug franchise Eylea, Roche on Thursday announced the FDA has expanded the label of its own blockbuster eye drug Vabysmo (faricimab-svoa) to a third indication, this time for the treatment of macular edema following retinal vein occlusion (RVO).

Click here to view original post